Basilea Pharmaceutica Forecast, price target & analysts
Basilea Pharmaceutica Target price 2026 - Analyst rating & recommendation
Basilea Pharmaceutica Classifications & Recommendation
Basilea Pharmaceutica Price Target
| Target Price | CHF112.20 |
| Price | CHF68.70 |
| Potential |
63.32%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Basilea Pharmaceutica 2027 .
The average Basilea Pharmaceutica target price is CHF112.20.
This is
63.32%
register free of charge
CHF126.00
83.41%
register free of charge
CHF70.70
2.91%
register free of charge
|
|
| A rating was issued by 11 analysts: 9 Analysts recommend Basilea Pharmaceutica to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Basilea Pharmaceutica stock has an average upside potential 2027 of
63.32%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million CHF | 232.38 | 269.13 |
| 11.43% | 15.81% | |
| EBITDA Margin | 22.96% | 29.60% |
| 23.88% | 28.91% | |
| Net Margin | 17.32% | 21.22% |
| 53.46% | 22.54% |
9 Analysts have issued a sales forecast Basilea Pharmaceutica 2026 . The average Basilea Pharmaceutica sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Basilea Pharmaceutica EBITDA forecast 2026. The average Basilea Pharmaceutica EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Basilea Pharmaceutica Analysts have issued a net profit forecast 2026. The average Basilea Pharmaceutica net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 2.94 | 4.61 |
| 47.50% | 56.80% | |
| P/E | 14.92 | |
| EV/Sales | 2.78 |
9 Analysts have issued a Basilea Pharmaceutica forecast for earnings per share. The average Basilea Pharmaceutica EPS is
This results in the following potential growth metrics and future valuations:
Basilea Pharmaceutica...
Current Basilea Pharmaceutica Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BAADER EUROPE |
Locked
➜
Locked
|
Locked | Aug 27 2026 |
| BAADER EUROPE |
Locked
➜
Locked
|
Locked | Aug 20 2026 |
| PARETO SECURITIES AS |
Locked
➜
Locked
|
Locked | Jun 24 2026 |
| PARETO SECURITIES AS |
Locked
➜
Locked
|
Locked | Jun 23 2026 |
| BAADER EUROPE |
Locked
➜
Locked
|
Locked | Jun 16 2026 |
| BAADER EUROPE |
Locked
➜
Locked
|
Locked | Jun 15 2026 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Feb 17 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BAADER EUROPE:
Locked
➜
Locked
|
Aug 27 2026 |
|
Locked
BAADER EUROPE:
Locked
➜
Locked
|
Aug 20 2026 |
|
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
|
Jun 24 2026 |
|
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
|
Jun 23 2026 |
|
Locked
BAADER EUROPE:
Locked
➜
Locked
|
Jun 16 2026 |
|
Locked
BAADER EUROPE:
Locked
➜
Locked
|
Jun 15 2026 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Feb 17 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
